Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Kazia Therapeutics Limited
KZIA | US
10.92
USD0.92
9.20%
KZIA | US
About Kazia Therapeutics Limited
Sector
Healthcare
Industry
Biotechnology
Earnings date
31/12/2023
As of date
16/04/2026
Close
10.92
Open
10.29
High
10.93
Low
9.50
Kazia Therapeutics Limited an oncology-focused biotechnology company develops anti-cancer drugs. Its lead development candidate is Paxalisib a small molecule brain-penetrant inhibitor of the PI3K/Akt/mTor pathway which is developed as a potential therapy for glioblastoma. It is also developing EVT801 an investigational new drug for various forms of cancer. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. The company was incorporated in 1994 and is based in Sydney Australia.
View LessKZIA | US
Risk
122.9
Sharpe
1.08
Luna's Score
60/100
Recommendation
Hold
Luna says (KZIA | US)
What's Working
Positive Momentum
Strength based on increasing price with high volume
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Strong Revenue Growth (> 10%)
What's not Working
High Short-term Volatility
High 6-Month Volatility (>65%)
Smallcap (300M - 2B USD)
High Market Beta (> 0.8)
Weak Operating Margin (< 10%)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
10 days
162.0%1 month
122.9%3 months
112.5%6 months
160.0%Returns
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
4.76
Debt to equity
0.07
Debt to assets
0.01
Ent. to EBITDA
-0.71
Ent. to rev.
0.94
PEG
-
Other Fundamentals
EBITDA
-17.52M
MarketCap
363.47M
MarketCap(USD)
363.47M
Div. yield
-
Op. margin
-100.00M
Erngs. growth
-
Rev. growth
35.60
Ret. on equity
-186.37
Short ratio
0.20
Short perc.
1.00
Market Sentiment (SMA and Price signals)
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
SMAs: Stock Price Trends
Range10D
3.92
Range1M
4.18
Range3M
6.14
Volumes: Market Activity
Rel. volume
1.57
Price X volume
3.09M
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -0.71 | - | Cheaper |
| Ent. to Revenue | 0.94 | - | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 4.76 | 15.55 | Cheaper |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 112.49 | - | Riskier |
| Debt to Equity | 0.07 | -1.23 | Expensive |
| Debt to Assets | 0.01 | 0.25 | Cheaper |
| Market Cap | 363.47M | - | Emerging |
